Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Aprea Therapeutics Q2 EPS $(0.58) Beats $(0.64) Estimate, Sales $561.57K Beat $50.00K Estimate

Author: Benzinga Newsdesk | August 12, 2024 08:41am
Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.64) by 9.38 percent. This is a 33.33 percent increase over losses of $(0.87) per share from the same period last year. The company reported quarterly sales of $561.57 thousand which beat the analyst consensus estimate of $50.00 thousand by 1.02K percent. This is a 124.91 percent increase over sales of $249.69 thousand the same period last year.

Posted In: APRE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist